Pulse Biosciences Inc
6 nominees · 5 ballot items.
Election of six directors; ratification of Deloitte & Touche LLP as independent registered public accounting firm for 2025; advisory vote on the compensation of Pulse Biosciences, Inc.'s named executive officers; advisory vote on the frequency of future advisory stockholder votes to approve executive compensation; and such other business as may properly come before the Annual Meeting.
Follow how the vote landed and what changed on Pulse Biosciences Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
On the ballot5
- 1
Election of six directors
ManagementBoard: FORElect six nominees to serve on Pulse Biosciences’ Board of Directors for one-year terms expiring at the 2026 annual meeting of stockholders.
- 2
Ratification of independent registered public accounting firm
ManagementBoard: FORRatify Deloitte & Touche LLP as Pulse Biosciences’ independent registered public accounting firm for the fiscal year ending December 31, 2025.
- 3
Advisory vote on executive compensation (say-on-pay
ManagementBoard: FORApprove, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement for the fiscal year ending December 31, 2024.
- 4
Advisory vote on the frequency of future advisory stockholder votes on executive compensation
ManagementBoard: FORVote on how frequently Pulse Biosciences should solicit advisory stockholder approval of executive compensation (every year, every 2 years, or every 3 years).
- 5
Other business
ManagementTransact such other business as may properly come before the Annual Meeting.
Nominees on the ballot6
Top institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BANK OF AMERICA CORP /DE/ | 1.3% | 866,061 | $19M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 1.2% | 815,852 | $18M |
| 3 | Portolan Capital Management, LLC | 1.1% | 733,372 | $16M |
| 4 | BlackRock, Inc. | 1.0% | 683,017 | $15M |
| 5 | BlackRock, Inc. | 0.7% | 493,117 | $11M |
| 6 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 0.7% | 462,899 | $10M |
| 7 | STATE STREET CORP | 0.7% | 456,927 | $10M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 0.6% | 428,167 | $9M |
| 9 | BALYASNY ASSET MANAGEMENT L.P. | 0.4% | 265,164 | $6M |
| 10 | GRIFFIN ASSET MANAGEMENT, INC. | 0.3% | 225,177 | $5M |
Other Healthcare sector meetings6
Upcoming shareholder meetings at Pulse Biosciences Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Frequently asked questions
- When is the Pulse Biosciences Inc 2025 annual meeting?
- Pulse Biosciences Inc (PLSE) holds its 2025 annual shareholder meeting on Tuesday, December 9, 2025.
- What is the record date for the Pulse Biosciences Inc 2025 meeting?
- The record date for the Pulse Biosciences Inc 2025 meeting is Wednesday, October 22, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Pulse Biosciences Inc's 2025 meeting?
- The board is presenting 6 director nominees at the Pulse Biosciences Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Pulse Biosciences Inc 2025 meeting?
- Shareholders will vote on 5 proposals at the Pulse Biosciences Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.